Overview

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Status:
Terminated

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety of TAS-119 and determine the most appropriate dose in combination with Paclitaxel for subsequent studies in patients with advanced solid tumors. TAS-119 is a novel, selective Aurora A kinase inhibitor, which has previously been demonstrated to enhance the activity of paclitaxel in preclinical studies

Phase:

Phase 1

Details

Lead Sponsor:

Taiho Oncology, Inc.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel